Ketamine and Esketamine: The Amazing, The Good, The Bad, and The Ugly

This activity is part of a series

Faculty

Charles B. Nemeroff, MD, PhD
Professor and Chair, Department of Psychiatry, The University of Texas at Austin, TX
Director, Institute of Early Life Adversity Research, Dell Medical School
Mulva Clinic for the Neurosciences
Charles B. Nemeroff, MD, PhD

Prior to joining Dell Med, Dr. Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida. He has served as president of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP) and sits on the Scientific Advisory Board and board of directors of the American Foundation for Suicide Prevention (AFSP) and the Anxiety and Depression Association of America (ADAA).

He is a member of the APA Council on Research and chairs both the APA Research Colloquium for Young Investigators and the APA Work Group on Biomarkers and Novel Treatments.

His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes and cancer. He has published more than 1,100 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.

He has also served on the Mental Health Advisory Council of National Institute of Mental Health and the Biomedical Research Council for NASA; is co-editor in chief (with Alan F. Schatzberg, M.D.) of the Textbook of Psychopharmacology, published by the APA Press and now in its fifth edition; co-editor in chief of a new text book on Post-Traumatic Stress Disorders, and is the co-editor in chief of a new journal published by Elsevier: Personalized Medicine in Psychiatry.

He received his M.D. and Ph.D. (Neurobiology) degrees at the University of North Carolina (UNC) School of Medicine. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke and at Emory University before relocating to the University of Miami in 2009.

Statement of Need

This video is a replay of a plenary session from the 12th Annual Chair Summit Master Class for Neuroscience Professional Development held in Las Vegas, NV from February 27 – 29, 2020.

Learning Objectives

At the end of this CME/CE activity, participants should be able to evaluate the latest evidence regarding the efficacy and side effects of ketamine and esketamine in patients with treatment resistant depression (TRD).

Financial Support

This activity is supported by CME Outfitters.

Target Audience

Physicians, physician assistants, nurse practitioners, nurses, and other healthcare professionals with an interest in psychiatry, neurology, and the neurosciences.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPN MOC

ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Note to PAs

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.


Dr. Nemeroff reports that he receives research and grant support from the National Institutes of Health (NIH). He is a consultant for ACADIA Pharmaceuticals Inc.; Bracket (Clintara); EMA Wellness; Gerson Lehrman Group, Inc. (GLG); Intra-Cellular Therapies, Inc.; Janssen Research & Development LLC; Magstim, Inc.; Navitor Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; TC MSO, Inc.; and Xhale, Inc. He holds stock in AbbVie Inc.; Antares Pharma; BI Gen Holdings, Inc.; Celgene Corporation; Corcept Therapeutics; EMA Wellness; OPKO Health Inc.; Seattle Genetics, Inc.; TC MSO, Inc.; Trends in Pharma Development, LLC; and Xhale, Inc. He serves on the board of directors for American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; and Xhale, Inc. He reports other income sources or equity of $10,000 or more from American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; EMA Wellness; Intra-Cellular Therapies, Inc.; Magstim, Inc.; and Xhale, Inc. He holds patents for Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2); Compounds, Compositions, Methods of Synthesis; and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,511,996B2).


Howard Bliwise, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

 


CHV-106-031621-00

Ketamine and Esketamine: The Amazing, The Good, The Bad, and The Ugly
Event Date: 03/16/2021